Contact
      Please use this form to send email to PR contact of this press release:
      
      Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
    
      TO: